title: Blood group incompatibility in kidney transplantation: definitely time to re-examine!
abstract: We report a successful kidney transplant (A1 donor to an O recipient), with antibody removal pre- and post-transplant, and pre-transplant administration of anti-CD20 monoclonal antibody (rituximab), intravenous immunoglobulin, and conventional transplant immunosuppression. The transplant, which was performed without splenectomy, is the first such transplant in Australia. At 20 months, the patient's creatinine level was 110-130 micromol/L, with no evidence of rejection and no complications. ABO-incompatible transplantation should increase "live donor" kidney transplantation, reduce waiting times, and improve patient outcomes.
authors.affiliation: Department of Nephrology, Royal Melbourne Hospital, Melbourne, VIC, Australia. solomon.cohney@mh.org.au
authors.forename: Shlomo J
authors.initials: SJ
authors.lastname: Cohney
authors.forename: Rowan G
authors.initials: RG
authors.lastname: Walker
authors.forename: Michael N
authors.initials: MN
authors.lastname: Haeusler
authors.forename: David M
authors.initials: DM
authors.lastname: Francis
authors.forename: Chris J
authors.initials: CJ
authors.lastname: Hogan
mesh_terms: D000328:Adult; D001787:Blood Group Incompatibility; D003404:Creatinine / Q000097:blood; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome
chemical_list: D003404:Creatinine